Disparities in pediatric acute myeloid leukemia (AML) clinical trial enrollment

Leuk Lymphoma. 2019 Sep;60(9):2190-2198. doi: 10.1080/10428194.2019.1574002. Epub 2019 Feb 7.

Abstract

Equal access to clinical trial enrollment is important to ensure that findings are generalizable to the broader population. This study aimed to evaluate disparities in enrollment on pediatric oncology clinical trials. We assessed the relationship between patient characteristics and enrollment on COG trial AAML1031 in a cohort of pediatric patients with AML in the Pediatric Health Information System. The associations of enrollment with outcomes were evaluated. Non-Hispanic Black patients, infants, and patients from zip codes with a lower proportion of poverty were less likely to enroll (30% vs. 61%, p = .004; 34% vs. 58%, p = .003; 46% vs. 58%, p = .02). On-therapy mortality was similar among enrolled and nonenrolled patients (7.3% vs. 8.9%, p = .47). Differences in early mortality were more pronounced among nonenrolled patients compared to enrolled patients (3.0% vs. 0.5%, p = .03). Understanding the etiology of these disparities will inform strategies to ensure balanced access to clinical trials across patient populations.

Keywords: Clinical trials; disparities; enrollment; leukemia; outcomes research; pediatric oncology; race/ethnicity.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Age Factors
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bortezomib / therapeutic use
  • Child
  • Child, Preschool
  • Clinical Trials, Phase III as Topic
  • Cohort Studies
  • Female
  • Health Services Accessibility / statistics & numerical data*
  • Healthcare Disparities / statistics & numerical data*
  • Humans
  • Infant
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / mortality
  • Male
  • Patient Selection*
  • Poverty / statistics & numerical data
  • Randomized Controlled Trials as Topic / statistics & numerical data*

Substances

  • Bortezomib